CompletedNot Applicable

Weight Loss in Patients With COVID-19 and Influenza in Comorbidity With NCDs: a Pilot Prospective Clinical Trial

Kazakhstan62 participantsStarted 2020-08-01

Plain-language summary

The goal of this study was to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs. Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan.

Who can participate

Age range25 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * written informed consent form; * patients with fever * patients refused for pharmacology therapy * weight loss treatment for 12-14 days and +4 weeks follow-up (total 6 weeks) Exclusion Criteria: * patients with acute respiratory failure and assisted ventilation requirement * respiratory rate ≥ 30 times per minute * oxygen saturation ≤ 93% by finger oximetry at resting status

What they're measuring

Clinic and infectious tests for COVID and Influenza

Timeframe: Change from Baseline at 6 Weeks

weight loss during 14 days

Timeframe: Change from Baseline at 14 days

C-reactive protein

Timeframe: Change from Baseline at 6 Weeks

Trial details

NCT IDNCT05635539

SponsorUniversity Medical Center, Kazakhstan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-30

View on ClinicalTrials.gov More Clinical Trial trials